Is Alzamend Neuro Inc (ALZN) a Buy, Sell, or Hold?
NASDAQ : ALZN
Alzamend Neuro Inc
$1.37 USD
-$0.01 (-0.72%)
- Volume
- 16.81K
- Average Volume
- 142.42K
- Market Capitalization
- $5.21M
- P/E Ratio
- -0.47
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.68
- Year Low
- $0.84
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.31
Company Overview
NASDAQ
Stephan Jackman
Biotechnology
Healthcare
ALZN
6
US
USD
Liquidity Metrics
0.00
1.31
1.31
0.53
0.00
Sales & Valuation
-$
0.00
6.24
-0.65
-2.42
Profitability
-$2.63
-$8.77M
0.00%
0.00%
-277.71%
-421.88%
P/E Metrics
-0.47
0.00
0.00
Analyst Price Target & Rating
1/5
2 Analysts
%
Financial Health Scores
-56.57
1/9
$418.34K
$2.08M
$1.35M
-$8.77M
Key Metrics (TTM)
$4.54M
0.00
-0.52
1.31
-277.71%
-1195.68%
-190.49%
-153.66%
-17748 days
Company Executives
| Name | Title |
|---|---|
| Milton Charles Ault | Founder & Vice Chairman |
| Kenneth S. Cragun | Senior Vice President of Finance |
| Stephan Jackman | Chief Executive Officer & Director |
| David J. Katzoff | Chief Financial Officer |
| Henry C. W. Nisser | Executive Vice President, General Counsel & Director |
Poll Results
No votes yet today — be the first to share your view!
About Alzamend Neuro Inc (NASDAQ:ALZN) Stock
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. ...
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
2026-08-04 08:00:00
Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs ATLANTA, Aug. 4, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that it has entered into a Securities Purchase Agreement (the "Agreement") with Ault Lending, LLC ("Ault Lending"), pursuant to which Ault Lending has agreed to purchase up to $25,000,000 of the Company's newly designated Series D Convertible Preferred Stock (the "Preferred Shares"), and closed on the initial tranche in the amount of $7.5 million. Under the terms of the Agreement, Ault Lending agreed to purchase up to 25,000 Preferred Shares at a purchase price of $1,000 per share, for an aggregate purchase price of $25,000,000, with each Preferred Share having a stated value of $1,050.
Frequently Asked Questions
-
What is the current Alzamend Neuro Inc (ALZN) stock price?
-
Alzamend Neuro Inc(NASDAQ:ALZN) stock price is $1.37 in the last trading session. During the trading session, ALZN stock reached the peak price of $2.68 while $0.84 was the lowest point it dropped to. The percentage change in ALZN stock occurred in the recent session was --0.72% while the dollar amount for the price change in ALZN stock was -$0.01.
-
ALZN's industry and sector of operation?
-
The NASDAQ listed ALZN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALZN?
-
Milton Charles Ault | Founder & Vice Chairman
Kenneth S. Cragun | Senior Vice President of Finance
Stephan Jackman | Chief Executive Officer & Director
David J. Katzoff | Chief Financial Officer
Henry C. W. Nisser | Executive Vice President, General Counsel & Director -
How many employees does ALZN have?
-
Number of ALZN employees currently stands at 6. ALZN operates from 3480 Peachtree Road NE, Atlanta, GA 30326, US.
-
Link for ALZN official website?
-
Official Website of ALZN is: https://www.alzamend.com
-
How do I contact ALZN?
-
ALZN could be contacted at phone #844 722 6333 and can also be accessed through its website. ALZN operates from 3480 Peachtree Road NE, Atlanta, GA 30326, US.
-
How many shares of ALZN are traded daily?
-
The average number of ALZN shares traded daily for last 3 months was 142.42K.
-
What is the market cap of ALZN currently?
-
The market value of ALZN currently stands at $5.21M with its latest stock price at $1.37